BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 2013;34:228-52. [PMID: 23872332 DOI: 10.1016/j.yfrne.2013.07.005] [Cited by in Crossref: 170] [Cited by in F6Publishing: 152] [Article Influence: 21.3] [Reference Citation Analysis]
Number Citing Articles
1 Wiedemann T, Pellegata NS. Animal models of multiple endocrine neoplasia. Mol Cell Endocrinol 2016;421:49-59. [PMID: 26184857 DOI: 10.1016/j.mce.2015.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wang Y, Goodman CL, Ringbauer J Jr, Li Y, Stanley D. Prostaglandin A2 induces apoptosis in three cell lines derived from the fall armyworm, Spodoptera frugiperda. Arch Insect Biochem Physiol 2021;108:e21844. [PMID: 34519097 DOI: 10.1002/arch.21844] [Reference Citation Analysis]
3 Daryaei I, Sandoval K, Witt K, Kontoyianni M, Michael Crider A. Discovery of a 3,4,5-trisubstituted-1,2,4-triazole agonist with high affinity and selectivity at the somatostatin subtype-4 (sst4) receptor. Medchemcomm 2018;9:2083-90. [PMID: 30746066 DOI: 10.1039/c8md00388b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
4 Maxwell JE, Sherman SK, Menda Y, Wang D, O'Dorisio TM, Howe JR. Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors. J Surg Res. 2014;190:548-553. [PMID: 24950794 DOI: 10.1016/j.jss.2014.05.031] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
5 Yadav S, Sharma AK, Kumar P. Nanoscale Self-Assembly for Therapeutic Delivery. Front Bioeng Biotechnol 2020;8:127. [PMID: 32158749 DOI: 10.3389/fbioe.2020.00127] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 33.0] [Reference Citation Analysis]
6 Krug S, Mordhorst JP, Moser F, Theuerkorn K, Ruffert C, Egidi M, Rinke A, Gress TM, Michl P. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells. PLoS One 2019;14:e0218953. [PMID: 31237925 DOI: 10.1371/journal.pone.0218953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
7 Gulde S, Wiedemann T, Schillmaier M, Valença I, Lupp A, Steiger K, Yen HY, Bäuerle S, Notni J, Luque R, Schmid H, Schulz S, Ankerst DP, Schilling F, Pellegata NS. Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors. Cancers (Basel) 2021;13:3097. [PMID: 34205778 DOI: 10.3390/cancers13123097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Lau A, Bourkas M, Lu YQQ, Ostrowski LA, Weber-Adrian D, Figueiredo C, Arshad H, Shoaei SZS, Morrone CD, Matan-Lithwick S, Abraham KJ, Wang H, Schmitt-Ulms G. Functional Amyloids and their Possible Influence on Alzheimer Disease. Discoveries (Craiova) 2017;5:e79. [PMID: 32309597 DOI: 10.15190/d.2017.9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
9 Ampofo E, Nalbach L, Menger MD, Laschke MW. Regulatory Mechanisms of Somatostatin Expression. Int J Mol Sci 2020;21:E4170. [PMID: 32545257 DOI: 10.3390/ijms21114170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Luque RM, Ibáñez-costa A, Sánchez-tejada L, Rivero-cortés E, Robledo M, Madrazo-atutxa A, Mora M, Álvarez CV, Lucas-morante T, Álvarez-escolá C, Fajardo C, Castaño L, Gaztambide S, Venegas-moreno E, Soto-moreno A, Gálvez MÁ, Salvador J, Valassi E, Webb SM, Picó A, Puig-domingo M, Gilabert M, Bernabéu I, Marazuela M, Leal-cerro A, Castaño JP. El Registro Molecular de Adenomas Hipofisarios (REMAH): una apuesta de futuro de la Endocrinología española por la medicina individualizada y la investigación traslacional. Endocrinología y Nutrición 2016;63:274-84. [DOI: 10.1016/j.endonu.2016.03.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
11 Fazekas-Singer J, Berroterán-Infante N, Rami-Mark C, Dumanic M, Matz M, Willmann M, Andreae F, Singer J, Wadsak W, Mitterhauser M, Jensen-Jarolim E. Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials. Oncotarget 2017;8:83128-41. [PMID: 29137329 DOI: 10.18632/oncotarget.20914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fujio S, Takano K, Arimura H, Habu M, Bohara M, Hirano H, Hanaya R, Nishio Y, Koriyama C, Kinoshita Y, Arita K. Treatable glomerular hyperfiltration in patients with active acromegaly. Eur J Endocrinol 2016;175:325-33. [PMID: 27440194 DOI: 10.1530/EJE-16-0242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
13 Singh P, Ray SB. Comparison of Antinociceptive Effect of Octreotide With Morphine in a Rat Model of Acute Inflammatory Pain. Ann Neurosci 2021;28:13-20. [PMID: 34733050 DOI: 10.1177/09727531211013004] [Reference Citation Analysis]
14 Xu C, Zhang H. Somatostatin receptor based imaging and radionuclide therapy. Biomed Res Int 2015;2015:917968. [PMID: 25879040 DOI: 10.1155/2015/917968] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
15 Zhao J, Wang S, Han S, Kim SH, Kusnetzow AK, Nguyen J, Rico-Bautista E, Tan H, Betz SF, Scott Struthers R, Zhu Y. Discovery of nonpeptide 3,4-dihydroquinazoline-4-carboxamides as potent and selective sst2 agonists. Bioorg Med Chem Lett 2020;30:127391. [PMID: 32738999 DOI: 10.1016/j.bmcl.2020.127391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Walker R, Deppen S, Smith G, Shi C, Lehman J, Clanton J, Moore B, Burns R, Grogan EL, Massion PP. 68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer. PLoS One. 2017;12:e0171301. [PMID: 28182730 DOI: 10.1371/journal.pone.0171301] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
17 Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 2018;14:552-61. [PMID: 30050156 DOI: 10.1038/s41574-018-0058-5] [Cited by in Crossref: 155] [Cited by in F6Publishing: 135] [Article Influence: 77.5] [Reference Citation Analysis]
18 Sáez-Martínez P, Jiménez-Vacas JM, León-González AJ, Herrero-Aguayo V, Montero Hidalgo AJ, Gómez-Gómez E, Sánchez-Sánchez R, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer. J Clin Med 2020;9:E1703. [PMID: 32498336 DOI: 10.3390/jcm9061703] [Reference Citation Analysis]
19 Hormaechea‐agulla D, Jiménez‐vacas JM, Gómez‐gómez E, López FL, Carrasco‐valiente J, Valero‐rosa J, Moreno MM, Sánchez‐sánchez R, Ortega‐salas R, Gracia‐navarro F, Culler MD, Ibáñez‐costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB j 2017;31:4682-96. [DOI: 10.1096/fj.201601264rrr] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
20 Edgerton DS, Kraft G, Smith MS, Moore LM, Farmer B, Scott M, Moore MC, Nauck MA, Cherrington AD. Effect of portal glucose sensing on incretin hormone secretion in a canine model. Am J Physiol Endocrinol Metab 2019;317:E244-9. [PMID: 31112407 DOI: 10.1152/ajpendo.00100.2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Paramonov VM, Desai D, Kettiger H, Mamaeva V, Rosenholm JM, Sahlgren C, Rivero-Müller A. Targeting Somatostatin Receptors By Functionalized Mesoporous Silica Nanoparticles - Are We Striking Home? Nanotheranostics 2018;2:320-46. [PMID: 30148051 DOI: 10.7150/ntno.23826] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Behling F, Fodi C, Skardelly M, Renovanz M, Castaneda S, Tabatabai G, Honegger J, Tatagiba M, Schittenhelm J. Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential. Neurosurg Rev 2021. [PMID: 33899156 DOI: 10.1007/s10143-021-01552-y] [Reference Citation Analysis]
23 Kool MM, Galac S, van der Helm N, Spandauw CG, Kooistra HS, Mol JA. Expression of somatostatin, dopamine, progesterone and growth hormone receptor mRNA in canine cortisol-secreting adrenocortical tumours. Vet J. 2015;206:108-110. [PMID: 26143682 DOI: 10.1016/j.tvjl.2015.05.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
24 Pepe S, Korbonits M, Iacovazzo D. Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects. J Endocrinol 2019;240:R21-45. [PMID: 30530903 DOI: 10.1530/JOE-18-0446] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
25 Lehman JM, Hoeksema MD, Staub J, Qian J, Harris B, Callison JC, Miao J, Shi C, Eisenberg R, Chen H, Chen SC, Massion PP. Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer. Int J Cancer 2019;144:1104-14. [PMID: 30152518 DOI: 10.1002/ijc.31771] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
26 Robaina Cabrera DM, Verde González MP, Tarazona Chocano B, Amado Fernández C, Zarrabeitia Puente R. Telangiectasia hemorrágica hereditaria: enfermedad de Rendu-Osler-Weber. FMC - Formación Médica Continuada en Atención Primaria 2016;23:446-58. [DOI: 10.1016/j.fmc.2016.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
27 Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas 2016;45:1386-93. [PMID: 27622342 DOI: 10.1097/MPA.0000000000000700] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 14.0] [Reference Citation Analysis]
28 Remes SM, Leijon HL, Vesterinen TJ, Arola JT, Haglund CH. Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias. J Histochem Cytochem 2019;67:735-43. [PMID: 31381461 DOI: 10.1369/0022155419856900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
29 Ibáñez-Costa A, López-Sánchez LM, Gahete MD, Rivero-Cortés E, Vázquez-Borrego MC, Gálvez MA, de la Riva A, Venegas-Moreno E, Jiménez-Reina L, Moreno-Carazo A, Tinahones FJ, Maraver-Selfa S, Japón MA, García-Arnés JA, Soto-Moreno A, Webb SM, Kineman RD, Culler MD, Castaño JP, Luque RM. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. Sci Rep 2017;7:42002. [PMID: 28181484 DOI: 10.1038/srep42002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
30 Leiszter K, Sipos F, Galamb O, Krenács T, Veres G, Wichmann B, Fűri I, Kalmár A, Patai ÁV, Tóth K, Valcz G, Tulassay Z, Molnár B. Promoter hypermethylation-related reduced somatostatin production promotes uncontrolled cell proliferation in colorectal cancer. PLoS One 2015;10:e0118332. [PMID: 25723531 DOI: 10.1371/journal.pone.0118332] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
31 Hernández-Ramírez LC, Trivellin G, Stratakis CA. Cyclic 3',5'-adenosine monophosphate (cAMP) signaling in the anterior pituitary gland in health and disease. Mol Cell Endocrinol 2018;463:72-86. [PMID: 28822849 DOI: 10.1016/j.mce.2017.08.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
32 Paragliola RM, Salvatori R. Novel Somatostatin Receptor Ligands Therapies for Acromegaly. Front Endocrinol (Lausanne) 2018;9:78. [PMID: 29563895 DOI: 10.3389/fendo.2018.00078] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
33 Solarski M, Williams D, Mehrabian M, Wang H, Wille H, Schmitt-Ulms G. The human brain somatostatin interactome: SST binds selectively to P-type family ATPases. PLoS One 2019;14:e0217392. [PMID: 31136617 DOI: 10.1371/journal.pone.0217392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Storvall S, Leijon H, Ryhänen E, Louhimo J, Haglund C, Schalin-Jäntti C, Arola J. Somatostatin receptor expression in parathyroid neoplasms. Endocr Connect 2019;8:1213-23. [PMID: 31336364 DOI: 10.1530/EC-19-0260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Luque RM, Villa-Osaba A, L-López F, Pozo-Salas AI, Sánchez-Sánchez R, Ortega-Salas R, de Lecea L, Álvarez-Benito M, López-Miranda J, Gahete MD, Castaño JP. Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode. Breast Cancer Res 2016;18:29. [PMID: 26956474 DOI: 10.1186/s13058-016-0689-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
36 Chen X, Zhang XY, Shen Y, Fan LL, Ren ML, Wu YP. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice. Oncotarget 2016;7:83451-61. [PMID: 27825139 DOI: 10.18632/oncotarget.13120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
37 Schernthaner-Reiter MH, Trivellin G, Stratakis CA. Chaperones, somatotroph tumors and the cyclic AMP (cAMP)-dependent protein kinase (PKA) pathway. Mol Cell Endocrinol 2020;499:110607. [PMID: 31586652 DOI: 10.1016/j.mce.2019.110607] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Kiviniemi A, Gardberg M, Kivinen K, Posti JP, Vuorinen V, Sipilä J, Rahi M, Sankinen M, Minn H. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome. Oncotarget 2017;8:49123-32. [PMID: 28467778 DOI: 10.18632/oncotarget.17097] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
39 Charron CL, Hickey JL, Nsiama TK, Cruickshank DR, Turnbull WL, Luyt LG. Molecular imaging probes derived from natural peptides. Nat Prod Rep 2016;33:761-800. [PMID: 26911790 DOI: 10.1039/c5np00083a] [Cited by in Crossref: 39] [Cited by in F6Publishing: 10] [Article Influence: 9.8] [Reference Citation Analysis]
40 Walls GV, Stevenson M, Soukup BS, Lines KE, Grossman AB, Schmid HA, Thakker RV. Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression. Endocrinology 2016;157:1789-98. [DOI: 10.1210/en.2015-1965] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
41 Liu J, Li H, Sun L, Wang Z, Xing C, Yuan Y. Aberrantly methylated-differentially expressed genes and pathways in colorectal cancer. Cancer Cell Int 2017;17:75. [PMID: 28794688 DOI: 10.1186/s12935-017-0444-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
42 Tang C, Ksiazek I, Siccardi N, Gapp B, Weber D, Wirsching J, Beck V, Reist M, Gaudet L, Stuber N, Surber SS, Mao X, Nicholson TB, Carbone W, Beibel M, Roma G, Gubser Keller C, Bassilana F. UTS2B Defines a Novel Enteroendocrine Cell Population and Regulates GLP-1 Secretion Through SSTR5 in Male Mice. Endocrinology 2019;160:2849-60. [PMID: 31556942 DOI: 10.1210/en.2019-00549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Herrera-martínez AD, Gahete MD, Sánchez-sánchez R, Salas RO, Serrano-blanch R, Salvatierra Á, Hofland LJ, Luque RM, Gálvez-moreno MA, Castaño JP. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. Lung Cancer 2017;109:128-36. [DOI: 10.1016/j.lungcan.2017.05.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
44 Rai U, Thrimawithana TR, Valery C, Young SA. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacol Ther 2015;152:98-110. [PMID: 25956467 DOI: 10.1016/j.pharmthera.2015.05.007] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 11.2] [Reference Citation Analysis]
45 Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev 2021;42:133-70. [PMID: 33249439 DOI: 10.1210/endrev/bnaa031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Lelle M, Kaloyanova S, Freidel C, Theodoropoulou M, Musheev M, Niehrs C, Stalla G, Peneva K. Octreotide-Mediated Tumor-Targeted Drug Delivery via a Cleavable Doxorubicin-Peptide Conjugate. Mol Pharm 2015;12:4290-300. [PMID: 26524088 DOI: 10.1021/acs.molpharmaceut.5b00487] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
47 Gadelha MR, Wildemberg LE, Kasuki L. The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 2021:dgab726. [PMID: 34618894 DOI: 10.1210/clinem/dgab726] [Reference Citation Analysis]
48 Subramani R, Nandy SB, Pedroza DA, Lakshmanaswamy R. Role of Growth Hormone in Breast Cancer. Endocrinology 2017;158:1543-55. [PMID: 28379395 DOI: 10.1210/en.2016-1928] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
49 Stengel A, Taché YF. Activation of Brain Somatostatin Signaling Suppresses CRF Receptor-Mediated Stress Response. Front Neurosci 2017;11:231. [PMID: 28487631 DOI: 10.3389/fnins.2017.00231] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
50 Syro LV, Rotondo F, Ramirez A, Di Ieva A, Sav MA, Restrepo LM, Serna CA, Kovacs K. Progress in the Diagnosis and Classification of Pituitary Adenomas. Front Endocrinol (Lausanne) 2015;6:97. [PMID: 26124750 DOI: 10.3389/fendo.2015.00097] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
51 Brand Y, Radojevic V, Sung M, Wei E, Setz C, Glutz A, Leitmeyer K, Bodmer D. Role of somatostatin receptor-2 in gentamicin-induced auditory hair cell loss in the Mammalian inner ear. PLoS One 2014;9:e108146. [PMID: 25268135 DOI: 10.1371/journal.pone.0108146] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
52 Liu F, Zhu H, Li C, Lin X, Xiong C, Li C, Yang Z. Design and radio-synthesis of somatostatin receptors targeted 68Ga-DOTA-Benereotide for non-invasive PET imaging. J Radioanal Nucl Chem 2016;307:1069-75. [DOI: 10.1007/s10967-015-4241-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Akaike T, Qazi J, Anderson A, Behnia FS, Shinohara MM, Akaike G, Hippe DS, Thomas H, Takagishi SR, Lachance K, Park SY, Tarabadkar ES, Iyer JG, Blom A, Parvathaneni U, Vesselle H, Nghiem P, Bhatia S. High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma. Br J Dermatol 2021;184:319-27. [PMID: 32320473 DOI: 10.1111/bjd.19150] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
54 Castellnou S, Vasiljevic A, Lapras V, Raverot V, Alix E, Borson-Chazot F, Jouanneau E, Raverot G, Lasolle H. SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors. Endocr Connect 2020:EC-20-0035. [PMID: 32101529 DOI: 10.1530/EC-20-0035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
55 Nilsson D, Henmyr V, Halldén C, Säll T, Kull I, Wickman M, Melén E, Cardell LO. Replication of genomewide associations with allergic sensitization and allergic rhinitis. Allergy 2014;69:1506-14. [PMID: 25066275 DOI: 10.1111/all.12495] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
56 Ayo A, Laakkonen P. Peptide-Based Strategies for Targeted Tumor Treatment and Imaging. Pharmaceutics 2021;13:481. [PMID: 33918106 DOI: 10.3390/pharmaceutics13040481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Jansson S, Fredén Lindqvist J, Manhem K, Nilsson O, Rosén T, Herlitz H. Quiz page June 2015: a young woman with hypertension. Am J Kidney Dis 2015;65:A17-9. [PMID: 26003613 DOI: 10.1053/j.ajkd.2015.01.027] [Reference Citation Analysis]
58 Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, de la Riva A, Arráez MÁ, González-Molero I, Schmid HA, Maraver-Selfa S, Gavilán-Villarejo I, García-Arnés JA, Japón MA, Soto-Moreno A, Gálvez MA, Luque RM, Castaño JP. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. J Endocrinol 2016;231:135-45. [PMID: 27587848 DOI: 10.1530/JOE-16-0332] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 8.4] [Reference Citation Analysis]
59 Lappano R, Maggiolini M. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. Drugs 2017;77:951-65. [PMID: 28401445 DOI: 10.1007/s40265-017-0738-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
60 Vázquez-Borrego MC, Gahete MD, Martínez-Fuentes AJ, Fuentes-Fayos AC, Castaño JP, Kineman RD, Luque RM. Multiple signaling pathways convey central and peripheral signals to regulate pituitary function: Lessons from human and non-human primate models. Mol Cell Endocrinol 2018;463:4-22. [PMID: 29253530 DOI: 10.1016/j.mce.2017.12.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
61 Stevenson M, Lines KE, Thakker RV. Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches. Endocrinol Metab Clin North Am 2018;47:525-48. [PMID: 30098714 DOI: 10.1016/j.ecl.2018.04.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
62 Störmann S, Schopohl J. Drug treatment strategies for secondary diabetes in patients with acromegaly. Expert Opin Pharmacother 2020;21:1883-95. [PMID: 32633582 DOI: 10.1080/14656566.2020.1789098] [Reference Citation Analysis]
63 Torniai M, Scortichini L, Tronconi F, Rubini C, Morgese F, Rinaldi S, Mazzanti P, Berardi R. Systemic treatment for lung carcinoids: from bench to bedside. Clin Transl Med 2019;8:22. [PMID: 31273555 DOI: 10.1186/s40169-019-0238-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
64 Lines KE, Filippakopoulos P, Stevenson M, Müller S, Lockstone HE, Wright B, Knapp S, Buck D, Bountra C, Thakker RV. Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells. Endocr Relat Cancer 2020;27:163-74. [PMID: 31935194 DOI: 10.1530/ERC-19-0448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
65 Lok CN, Zou T, Zhang JJ, Lin IW, Che CM. Controlled-release systems for metal-based nanomedicine: encapsulated/self-assembled nanoparticles of anticancer gold(III)/platinum(II) complexes and antimicrobial silver nanoparticles. Adv Mater 2014;26:5550-7. [PMID: 24664412 DOI: 10.1002/adma.201305617] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
66 Kunos CA, Rubinstein LV, Capala J, McDonald MA. Phase 0 Radiopharmaceutical-Agent Clinical Development. Front Oncol 2020;10:1310. [PMID: 33014772 DOI: 10.3389/fonc.2020.01310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Bao X, Wang G, Yu S, Sun J, He L, Zhao H, Ma Y, Wang F, Wang X, Wang R, Yu J. Transcriptomic analysis identifies a tumor subtype mRNA classifier for invasive non-functioning pituitary neuroendocrine tumor diagnostics. Theranostics 2021;11:132-46. [PMID: 33391466 DOI: 10.7150/thno.47525] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
68 Sievers C, Baur DM, Schwanke A, Buchfelder M, Droste M, Mann K, Stalla GK. Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort. Pituitary 2015;18:916-23. [PMID: 26224528 DOI: 10.1007/s11102-015-0673-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
69 Vitali E, Piccini S, Trivellin G, Smiroldo V, Lavezzi E, Zerbi A, Pepe G, Lania AG. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. Mol Cell Endocrinol 2021;527:111226. [PMID: 33675866 DOI: 10.1016/j.mce.2021.111226] [Reference Citation Analysis]
70 Kidd M, Modlin IM, Bodei L, Drozdov I. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. Cell Mol Gastroenterol Hepatol 2015;1:131-53. [PMID: 28210673 DOI: 10.1016/j.jcmgh.2014.12.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
71 Kecskés A, Pohóczky K, Kecskés M, Varga ZV, Kormos V, Szőke É, Henn-Mike N, Fehér M, Kun J, Gyenesei A, Renner É, Palkovits M, Ferdinandy P, Ábrahám IM, Gaszner B, Helyes Z. Characterization of Neurons Expressing the Novel Analgesic Drug Target Somatostatin Receptor 4 in Mouse and Human Brains. Int J Mol Sci 2020;21:E7788. [PMID: 33096776 DOI: 10.3390/ijms21207788] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
72 Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer 2014;9:27. [PMID: 25225571 DOI: 10.1186/1750-9378-9-27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
73 Gatto F, Barbieri F, Arvigo M, Thellung S, Amarù J, Albertelli M, Ferone D, Florio T. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. Int J Mol Sci 2019;20:E3940. [PMID: 31412614 DOI: 10.3390/ijms20163940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
74 Hu B, Cilz NI, Lei S. Somatostatin depresses the excitability of subicular bursting cells: Roles of inward rectifier K+ channels, KCNQ channels and Epac. Hippocampus 2017;27:971-84. [PMID: 28558129 DOI: 10.1002/hipo.22744] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
75 De Jonge HR, Tilly BC, Hogema BM, Pfau DJ, Kelley CA, Kelley MH, Melita AM, Morris MT, Viola RM, Forrest JN Jr. cGMP inhibition of type 3 phosphodiesterase is the major mechanism by which C-type natriuretic peptide activates CFTR in the shark rectal gland. Am J Physiol Cell Physiol 2014;306:C343-53. [PMID: 24259420 DOI: 10.1152/ajpcell.00326.2013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
76 Perez K, Chan J. Treatment of Gastroenteropancreatic Neuroendocrine Tumors. Surgical Pathology Clinics 2019;12:1045-53. [DOI: 10.1016/j.path.2019.08.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
77 Soukup J, Kasparova P, Kohout A, Rychly B, Skarkova V, Syrucek M, Gabalec F. Evaluation of expression of somatostatin receptor 1, 2, 3, 5 and dopamine D2 receptor in spindle cell oncocytomas of posterior pituitary. Pituitary 2019;22:70-8. [DOI: 10.1007/s11102-018-00935-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Herrera-Martínez AD, Gahete MD, Pedraza-Arevalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018;59:426-37. [PMID: 29196939 DOI: 10.1007/s12020-017-1482-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
79 Loos JA, Negro P, Cumino AC. In vitro anti-echinococcal activity of octreotide: Additive effect of metformin linked to autophagy. Acta Trop 2020;203:105312. [PMID: 31870710 DOI: 10.1016/j.actatropica.2019.105312] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Vázquez-borrego MC, Fuentes-fayos AC, Herrera-martínez AD, L-lópez F, Ibáñez-costa A, Moreno-moreno P, Alhambra-expósito MR, Barrera-martín A, Blanco-acevedo C, Dios E, Venegas-moreno E, Solivera J, Gahete MD, Soto-moreno A, Gálvez-moreno MA, Castaño JP, Luque RM. Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms. The Journal of Clinical Endocrinology & Metabolism 2019;104:3501-13. [DOI: 10.1210/jc.2019-00056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
81 Askari Rizvi SF, Zhang H. Emerging trends of receptor-mediated tumor targeting peptides: A review with perspective from molecular imaging modalities. Eur J Med Chem 2021;221:113538. [PMID: 34022717 DOI: 10.1016/j.ejmech.2021.113538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Suleiman Y, Mahipal A, Shibata D, Siegel EM, Jump H, Fulp WJ, Springett GM, Kim R. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2015;76:481-487. [PMID: 26126727 DOI: 10.1007/s00280-015-2814-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
83 Behling F, Honegger J, Skardelly M, Gepfner-Tuma I, Tabatabai G, Tatagiba M, Schittenhelm J. High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma. Int J Endocrinol 2018;2018:1763735. [PMID: 30627156 DOI: 10.1155/2018/1763735] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
84 Panda A, Garg I, Johnson GB, Truty MJ, Halfdanarson TR, Goenka AH. Molecular radionuclide imaging of pancreatic neoplasms. The Lancet Gastroenterology & Hepatology 2019;4:559-70. [DOI: 10.1016/s2468-1253(19)30081-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
85 Zhang M, Lv X, Jiang Y, Li G, Qiao Q. Identification of aberrantly methylated differentially expressed genes in glioblastoma multiforme and their association with patient survival. Exp Ther Med 2019;18:2140-52. [PMID: 31452706 DOI: 10.3892/etm.2019.7807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
86 Sampedro-Núñez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibáñez-Costa A, Martín-Pérez E, Culler MD, Marazuela M, Castaño JP. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Oncotarget 2016;7:6593-608. [PMID: 26673010 DOI: 10.18632/oncotarget.6565] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
87 Amarù J, Barbieri F, Arvigo M, Solari A, Bajetto A, Nista F, Campana C, Gaggero G, Prior A, Criminelli Rossi D, Zona G, Ferone D, Florio T, Gatto F. Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects. Cancers (Basel) 2021;13:1816. [PMID: 33920241 DOI: 10.3390/cancers13081816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Greenman Y. MANAGEMENT OF ENDOCRINE DISEASE: Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas. European Journal of Endocrinology 2017;177:R113-24. [DOI: 10.1530/eje-17-0216] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
89 Rol Á, Todorovski T, Martin-Malpartida P, Escolà A, Gonzalez-Rey E, Aragón E, Verdaguer X, Vallès-Miret M, Farrera-Sinfreu J, Puig E, Fernández-Carneado J, Ponsati B, Delgado M, Riera A, Macias MJ. Structure-based design of a Cortistatin analogue with immunomodulatory activity in models of inflammatory bowel disease. Nat Commun 2021;12:1869. [PMID: 33767180 DOI: 10.1038/s41467-021-22076-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO, Kerr JM, Kleinschmidt-DeMasters BK, Wierman ME. Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol 2015;417:73-83. [PMID: 26391562 DOI: 10.1016/j.mce.2015.09.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
91 Yates CJ, Lines KE, Thakker RV. Molecular genetic advances in pituitary tumor development. Expert Review of Endocrinology & Metabolism 2014;10:35-53. [DOI: 10.1586/17446651.2015.955795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
92 Michael M, Garcia-Carbonero R, Weber MM, Lombard-Bohas C, Toumpanakis C, Hicks RJ. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. Oncologist 2017;22:272-85. [PMID: 28220021 DOI: 10.1634/theoncologist.2016-0305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
93 Barbeito P, Garcia-Gonzalo FR. HTR6 and SSTR3 targeting to primary cilia. Biochem Soc Trans 2021;49:79-91. [PMID: 33599752 DOI: 10.1042/BST20191005] [Reference Citation Analysis]
94 Liang X, Mao Q, Huang D, Tang J, Zheng J. Overexpression of cortistatin alleviates oxygen/glucose-deprivation-induced ER stress and prompts neural stem cell proliferation via SSTR2. Exp Mol Pathol 2020;113:104351. [PMID: 31809712 DOI: 10.1016/j.yexmp.2019.104351] [Reference Citation Analysis]
95 Basu S, Parghane RV, Kamaldeep, Chakrabarty S. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. Seminars in Nuclear Medicine 2020;50:447-64. [DOI: 10.1053/j.semnuclmed.2020.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
96 Maxwell JE, Sherman SK, Howe JR. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clin Cancer Res 2016;22:5022-9. [PMID: 27742788 DOI: 10.1158/1078-0432.CCR-16-0435] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
97 Walsh KB, Gay EA, Blough BE, Geurkink DW. N-(2-methoxyphenyl) benzenesulfonamide, a novel regulator of neuronal G protein-gated inward rectifier K + channels. European Journal of Pharmacology 2017;815:233-40. [DOI: 10.1016/j.ejphar.2017.09.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Sakai K, Yonezawa T, Yamawaki H, Oyamada T. Alteration of somatostatin receptor 2 expression in canine mammary gland tumor. J Vet Med Sci 2015;77:1319-22. [PMID: 25985817 DOI: 10.1292/jvms.15-0002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
99 Huang X, Xue J, Gao M, Qin Q, Ma T, Li X, Wang H. Medical Management of Inoperable Malignant Bowel Obstruction. Ann Pharmacother 2021;55:1134-45. [PMID: 33345552 DOI: 10.1177/1060028020979773] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Karaca B, Degirmenci M, Ozveren A, Atmaca H, Bozkurt E, Karabulut B, Sanli UA, Uslu R. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines. Cancer Chemother Pharmacol 2015;75:1273-80. [DOI: 10.1007/s00280-015-2756-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
101 Kendler DB, Araújo Jr ML, Alencar R, de Souza Accioly MT, Bulzico DA, de Noronha Pessoa CC, Accioly FA, de Farias TP, Lopes FPPL, Corbo R, Vaisman M, Vaisman F. Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma. Endocrine 2017;58:474-80. [DOI: 10.1007/s12020-017-1424-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
102 Modarai SR, Opdenaker LM, Viswanathan V, Fields JZ, Boman BM. Somatostatin signaling via SSTR1 contributes to the quiescence of colon cancer stem cells. BMC Cancer 2016;16:941. [PMID: 27927191 DOI: 10.1186/s12885-016-2969-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
103 Hijioka S, Morizane C, Ikeda M, Ishii H, Okusaka T, Furuse J. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Jpn J Clin Oncol 2021;51:1185-96. [PMID: 34038547 DOI: 10.1093/jjco/hyab076] [Reference Citation Analysis]
104 Sanjuan-Sanjuan A, Alors-Perez E, Sanchez-Frías M, Dean-Ferrer A, Gahete MD, Heredero-Jung S, Luque RM. Molecular and Clinical Implications of Somatostatin Receptor Profile and Somatostatin Analogues Treatment in Oral Cavity Squamous Cell Carcinoma. Cancers (Basel) 2021;13:4828. [PMID: 34638313 DOI: 10.3390/cancers13194828] [Reference Citation Analysis]
105 Cantone MC, Dicitore A, Vitale G. Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms. J Clin Med 2021;10:501. [PMID: 33535394 DOI: 10.3390/jcm10030501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
106 Streuli J, Harris AG, Cottiny C, Allagnat F, Daly AF, Grouzmann E, Abid K. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors. Neuropeptides 2018;68:84-9. [PMID: 29523357 DOI: 10.1016/j.npep.2018.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
107 Lee M, Lupp A, Mendoza N, Martin N, Beschorner R, Honegger J, Schlegel J, Shively T, Pulz E, Schulz S, Roncaroli F, Pellegata NS. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocr Relat Cancer 2015;22:111-9. [PMID: 25515731 DOI: 10.1530/ERC-14-0472] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
108 Ibáñez-costa A, Luque RM, Castaño JP. Cortistatin: A new link between the growth hormone/prolactin axis, stress, and metabolism. Growth Hormone & IGF Research 2017;33:23-7. [DOI: 10.1016/j.ghir.2017.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
109 Cheng Y, Chen T, Song J, Qi Q, Wang C, Xi Q, Liu S, Hao L, Zhang Y. miR-709 inhibits GHRP6 induced GH synthesis by targeting PRKCA in pituitary. Mol Cell Endocrinol 2020;506:110763. [PMID: 32084499 DOI: 10.1016/j.mce.2020.110763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Iacovazzo D, Hernández-ramírez L, Korbonits M. Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening. Expert Review of Endocrinology & Metabolism 2017;12:143-53. [DOI: 10.1080/17446651.2017.1306439] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
111 Tulipano G, Faggi L, Schulz S, Spinello M, Giustina A. Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells. Endocrine 2017;57:179-82. [PMID: 28120181 DOI: 10.1007/s12020-017-1235-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
112 Maxwell JE, O'Dorisio TM, Howe JR. Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2016;25:171-94. [PMID: 26610781 DOI: 10.1016/j.soc.2015.08.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
113 Szkukalek J, Dóczi R, Dirner A, Boldizsár Á, Varga Á, Déri J, Lakatos D, Tihanyi D, Vodicska B, Schwáb R, Pajkos G, Várkondi E, Vályi-Nagy I, Valtinyi D, Nagy Z, Peták I. Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support. Diagnostics (Basel) 2021;11:1850. [PMID: 34679548 DOI: 10.3390/diagnostics11101850] [Reference Citation Analysis]
114 Jiang Q, Wong AO. Somatostatin-28 inhibitory action on somatolactin-α and -β gene expression in goldfish. Am J Physiol Regul Integr Comp Physiol 2014;307:R755-68. [PMID: 25009216 DOI: 10.1152/ajpregu.00193.2014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
115 Ando H, Ushijima K, Shimba S, Fujimura A. Daily Fasting Blood Glucose Rhythm in Male Mice: A Role of the Circadian Clock in the Liver. Endocrinology 2016;157:463-9. [PMID: 26653333 DOI: 10.1210/en.2015-1376] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
116 Reynaert H, Colle I. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. Int J Mol Sci 2019;20:E4811. [PMID: 31569719 DOI: 10.3390/ijms20194811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
117 Nagarajan SK, Babu S, Sohn H, Madhavan T. Molecular-Level Understanding of the Somatostatin Receptor 1 (SSTR1)-Ligand Binding: A Structural Biology Study Based on Computational Methods. ACS Omega 2020;5:21145-61. [PMID: 32875251 DOI: 10.1021/acsomega.0c02847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
118 Alhambra-Expósito MR, Ibáñez-Costa A, Moreno-Moreno P, Rivero-Cortés E, Vázquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado Á, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castaño JP, Gálvez MA, Luque RM. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. Sci Rep 2018;8:6173. [PMID: 29670116 DOI: 10.1038/s41598-018-24260-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
119 Maas M, Mayer L, Hennenlotter J, Stühler V, Walz S, Scharpf M, Kühs U, Neumann T, Stenzl A, Todenhöfer T. Prognostic impact of somatostatin receptor expression in advanced bladder cancer. Urol Oncol 2020;38:935.e17-28. [PMID: 32773234 DOI: 10.1016/j.urolonc.2020.07.005] [Reference Citation Analysis]
120 Gatto F, Arvigo M, Amarù J, Campana C, Cocchiara F, Graziani G, Bruzzone E, Giusti M, Boschetti M, Ferone D. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary 2019;22:89-99. [PMID: 30483918 DOI: 10.1007/s11102-018-0926-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
121 Vesterinen T, Leijon H, Mustonen H, Remes S, Knuuttila A, Salmenkivi K, Vainio P, Arola J, Haglund C. Somatostatin Receptor Expression Is Associated With Metastasis and Patient Outcome in Pulmonary Carcinoid Tumors. The Journal of Clinical Endocrinology & Metabolism 2019;104:2083-93. [DOI: 10.1210/jc.2018-01931] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
122 Vitali E, Cambiaghi V, Zerbi A, Carnaghi C, Colombo P, Peverelli E, Spada A, Mantovani G, Lania AG. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours. Endocr Relat Cancer 2016;23:181-90. [PMID: 26733502 DOI: 10.1530/ERC-15-0358] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
123 Wildemberg LE, Gadelha MR. Pasireotide for the treatment of acromegaly. Expert Opinion on Pharmacotherapy 2015;17:579-88. [DOI: 10.1517/14656566.2016.1146688] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
124 del Rio-moreno M, Alors-perez E, Borges de Souza P, Prados-gonzalez ME, Castaño JP, Luque RM, Gahete MD. Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. Translational Research 2019;211:147-60. [DOI: 10.1016/j.trsl.2019.02.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
125 Øystese KA, Casar-Borota O, Normann KR, Zucknick M, Berg JP, Bollerslev J. Estrogen Receptor α, a Sex-Dependent Predictor of Aggressiveness in Nonfunctioning Pituitary Adenomas: SSTR and Sex Hormone Receptor Distribution in NFPA. J Clin Endocrinol Metab 2017;102:3581-90. [PMID: 28911153 DOI: 10.1210/jc.2017-00792] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
126 Russo D, Merolla F, Varricchio S, Salzano G, Zarrilli G, Mascolo M, Strazzullo V, Di Crescenzo RM, Celetti A, Ilardi G. Epigenetics of oral and oropharyngeal cancers. Biomed Rep 2018;9:275-83. [PMID: 30233779 DOI: 10.3892/br.2018.1136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
127 Sala E, Carosi G, Del Sindaco G, Mungari R, Cremaschi A, Serban AL, Ronchi CL, Ferrante E, Arosio M, Mantovani G. Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience. J Endocrinol Invest 2021. [PMID: 34018167 DOI: 10.1007/s40618-021-01562-z] [Reference Citation Analysis]
128 Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
129 Luque RM, Ibáñez-Costa A, Neto LV, Taboada GF, Hormaechea-Agulla D, Kasuki L, Venegas-Moreno E, Moreno-Carazo A, Gálvez MÁ, Soto-Moreno A, Kineman RD, Culler MD, Gahete MD, Gadelha MR, Castaño JP. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas. Cancer Lett 2015;359:299-306. [PMID: 25637790 DOI: 10.1016/j.canlet.2015.01.037] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
130 Zanjani FS, Gaeni AA, Aras D, Akalan C. The effect of strength and endurance training on SSTR2 and SSTR5 in patients with colorectal cancer. J Exerc Rehabil 2019;15:622-7. [PMID: 31523687 DOI: 10.12965/jer.1938250.125] [Reference Citation Analysis]
131 Korde A, Mallia M, Shinto A, Sarma H, Samuel G, Banerjee S. Improved Kit Formulation for Preparation of 99m Tc-HYNIC-TOC: Results of Preliminary Clinical Evaluation in Imaging Patients with Neuroendocrine Tumors. Cancer Biotherapy and Radiopharmaceuticals 2014;29:387-94. [DOI: 10.1089/cbr.2014.1657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
132 Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA network. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathol Commun 2018;6:89. [PMID: 30193580 DOI: 10.1186/s40478-018-0594-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
133 Yamamoto M, Ben-Shlomo A, Kameda H, Fukuoka H, Deng N, Ding Y, Melmed S. Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function. JCI Insight 2018;3:122932. [PMID: 30282821 DOI: 10.1172/jci.insight.122932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
134 Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018;70:763-835. [PMID: 30232095 DOI: 10.1124/pr.117.015388] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 35.0] [Reference Citation Analysis]
135 Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov 2021;20:309-25. [PMID: 33536635 DOI: 10.1038/s41573-020-00135-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 42.0] [Reference Citation Analysis]
136 Wu W, Zhou Y, Wang Y, Liu L, Lou J, Deng Y, Zhao P, Shao A. Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma. Front Oncol 2020;10:1633. [PMID: 33014821 DOI: 10.3389/fonc.2020.01633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Antelo G, Hierro C, Fernández JP, Baena E, Bugés C, Layos L, Manzano JL, Caro M, Mesia R. Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents. Drugs Context 2020;9:2020-2-4. [PMID: 32477420 DOI: 10.7573/dic.2020-2-4] [Reference Citation Analysis]
138 Zou Y, Tan H, Zhao Y, Zhou Y, Cao L. Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells. Oncol Lett 2019;17:1723-31. [PMID: 30675231 DOI: 10.3892/ol.2018.9773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
139 Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am 2016;30:163-77. [PMID: 26614375 DOI: 10.1016/j.hoc.2015.09.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
140 Sakata K, Fujimori K, Komaki S, Furuta T, Sugita Y, Ashida K, Nomura M, Morioka M. Pituitary Gangliocytoma Producing TSH and TRH: A Review of "Gangliocytomas of the Sellar Region". J Clin Endocrinol Metab 2020;105:dgaa474. [PMID: 32706866 DOI: 10.1210/clinem/dgaa474] [Reference Citation Analysis]
141 Barrett KE, Houson HA, Lin W, Lapi SE, Engle JW. Production, Purification, and Applications of a Potential Theranostic Pair: Cobalt-55 and Cobalt-58m. Diagnostics (Basel) 2021;11:1235. [PMID: 34359318 DOI: 10.3390/diagnostics11071235] [Reference Citation Analysis]
142 Visentin M, Stieger B, Merz M, Kullak-ublick GA. Octreotide Inhibits the Bilirubin Carriers Organic Anion Transporting Polypeptides 1B1 and 1B3 and the Multidrug Resistance-Associated Protein 2. J Pharmacol Exp Ther 2015;355:145-51. [DOI: 10.1124/jpet.115.227546] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
143 Ibáñez-Costa A, Korbonits M. AIP and the somatostatin system in pituitary tumours. J Endocrinol 2017;235:R101-16. [PMID: 28835453 DOI: 10.1530/JOE-17-0254] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
144 Colao A, Auriemma RS, Pivonello R. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary 2016;19:210-21. [PMID: 26290466 DOI: 10.1007/s11102-015-0677-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
145 Störmann S, Schopohl J. New and emerging drug therapies for Cushing's disease. Expert Opin Pharmacother 2018;19:1187-200. [PMID: 30048162 DOI: 10.1080/14656566.2018.1504021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
146 Maharjan CK, Ear PH, Tran CG, Howe JR, Chandrasekharan C, Quelle DE. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers (Basel) 2021;13:5117. [PMID: 34680266 DOI: 10.3390/cancers13205117] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Liolios CC, Xanthopoulos S, Loudos G, Varvarigou AD, Sivolapenko GB. Co-administration of succinylated gelatine with a (99m)Tc-bombesin analogue, effects on pharmacokinetics and tumor uptake. Nucl Med Biol 2016;43:625-34. [PMID: 27497631 DOI: 10.1016/j.nucmedbio.2016.07.005] [Reference Citation Analysis]
148 Pujato M, Kieken F, Skiles AA, Tapinos N, Fiser A. Prediction of DNA binding motifs from 3D models of transcription factors; identifying TLX3 regulated genes. Nucleic Acids Res 2014;42:13500-12. [PMID: 25428367 DOI: 10.1093/nar/gku1228] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
149 Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther 2018;181:49-75. [PMID: 28723416 DOI: 10.1016/j.pharmthera.2017.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
150 Lehman JM, aMassion PP. Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives. Oncotarget 2019;10:4727-30. [PMID: 31413814 DOI: 10.18632/oncotarget.27107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Störmann S, Schopohl J. Emerging drugs for acromegaly. Expert Opin Emerg Drugs 2014;19:79-97. [PMID: 24400774 DOI: 10.1517/14728214.2014.875529] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
152 Li K, Shen M, Geng H, Zheng L, Cao Y. Computed Tomographic Studies of Noncalcified Nodules Related to Neuroendocrine Lung Tumor Using 68Gallium-Tagged Somatostatin Variant for Improvement in Diagnosis: A Non-Experimental, Non-Randomized, Cross-Sectional Study. Med Sci Monit 2018;24:4501-9. [PMID: 29959846 DOI: 10.12659/MSM.908545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]